University of Vienna:
1973: Graduation for PhD
1975: Graduation for MD;
Training in surgery, paediatrics and internal medicine at the Kaiser Franz Josef Hospital of the City of Vienna
1980: Assistant Professor at the University of Vienna, Department of Gynaecology and Obstetrics
1985: Associate Professor at the University of Vienna, Department of Gynaecology and Obstetrics
1993: Head of the Division for Gynaecological Endocrinology an Infertility Treatment at the University of Vienna
1995: Chairman of the Department of Gynaecology, University of Vienna, General Hospital of Vienna
Medical training at the midwifery School, Zurich / Switzerland
Medical training at the Department of Gynaecology, University of Basel
Visiting Professor at John Hopkins University
Visiting Professor at George Washington University
Member of the Editorial Board of “Wiener Medizinsche Wochenschrift”
Member of the Editorial Board of “Clinical Pharmacology”
Secretary of the Austrian Society for Infertility Treatment
Member of the Board of Directors of Austrian Society for IVF
Member of the Board of Directors of Austrian Society of Endocrinology
Executive Member of the Austrian Society for Contraception
Member of the Supreme Austrian Health Organisation (Oberster Sanitätsrat)
Member of the Supreme Court for Health in Austria
Expert of the Austrian Parliament (Nationalrat) for Assisted Reproduction
Expert of Special Committee for Contraceptives in the German Bundestag
Chairman of the National Committee of Bioethics of the Austrian Government
Developing the firs DNA analyser of single nucleotide polymorphisms for improvement of
hormone replacement therapy
Mean Research Projects Gender Specific Medicine and Combined Endoscopical Endocrine
Surgery

Abstract
J. C. Huber
"Genetic prevention of breast and prostatic cancer"

Single nucleotide polymorphism diagnostic becomes more and more important for the clinical practice. Metaanalysis indicate, that the polymorphic gen constructer of the CYP 19 gen is associated with a high incidence of breast cancer . Aromatise activity can be suppressed by pharmacological drugs but also by phytosteroids and by life style recommendations. Therefore the knowledge of this genotype becomes important for prevention. The same is true for the polymorphism in the androgen receptor gen. Prospective studies are available showing that the genotype with allow androgen activity is associated with a higher risk also for breast cancer. 
For prevention of prostatic cancer five difference in nucleotide polymorphism are investigated and are associated with a higher risk for this endocrine related cancer. Preventive oncology is an important aspect of molecular medicine and the knowledge of single nucleotide polymorphism is important in this new area of medicine.